| Symbol | CTTH |
|---|---|
| Name | CTT PHARMACEUTICAL HOLDINGS, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 33624 United States FL 3853 Northdale Blvd #268 |
| Telephone | +1 813-606-0060 |
| Fax | — |
| — | |
| Website | http://www.cttpharmaceuticals.com |
| Incorporation | US |
| Incorporated On | 1996 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Holt & Patterson, LLC; |
| Audit Status | AUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0001035422 |
| Description | CTTHs principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in major markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the US, Canada, Europe and many other countries across the world. Additional info from OTC: |
CTT Pharma and Johns Hopkins University Submits Proposal For $15 MillionNIH Grant For Smoking Cessation
Read more